Gilead

Nucleai says it has used AI to analyze H&E and IHC whole-slide images from several Gilead oncology clinical studies in support of Gilead's ADC clinical programs, generating candidate spatial biomarkers.

Partners: Nucleai

Gilead and Terray announced a multi-target collaboration using Terray's tNova platform, which combines high-throughput chemistry with a generative AI discovery engine.

Partners: Terray Therapeutics

Gilead and Genesis Therapeutics announced a collaboration using Genesis's GEMS AI platform to generate and jointly optimize molecules against selected targets.

Partners: Genesis Therapeutics

Tempus announced an expanded collaboration giving Gilead enterprise-wide access to Tempus's AI-driven Lens platform and multimodal data for oncology R&D and real-world evidence.

Partners: Tempus AI

Gilead broke ground on a biologics Technical Development Center it says will feature digitally enabled systems, autonomous robotics and real-time monitoring. The company describes the site as one of the biopharma industry's most AI-enabled centers.

AWS blog co-authored by Gilead's CIO says Gilead uses specialized LLMs to query and summarize literature and databases for drug-target assessment, aiming to cut assessment time by months.

Partners: AWS